Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon regulatory factor 5 messenger RNA nanoparticles + I-kappa-B kinase beta messenger RNA nanoparticles
- Development stage
- Preclinical
- Lead developer
- Fred Hutchinson Cancer Research Institute
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Interferon regulatory factor 5 (IRF5) messenger RNA nanoparticles + I-kappa-B kinase beta (IKKβ) messenger RNA nanoparticles is an experimental combination immunotherapy designed to reprogram tumor-associated macrophages (TAMs). TAMs typically exhibit an immunosuppressive M2 phenotype that promotes tumor growth. This therapy uses targeted nanocarriers to deliver in vitro-transcribed mRNA encoding the M1-polarizing transcription factor IRF5 and its activating kinase IKKβ directly to TAMs. By expressing these factors, the macrophages are shifted toward a pro-inflammatory M1 phenotype, which triggers anti-tumor immunity and promotes tumor regression. Preclinical studies have demonstrated efficacy and safety in models of ovarian cancer, melanoma, and glioblastoma.
- Other names
- IRF5 mRNA nanoparticles + IKKβ mRNA nanoparticlesIRF5/IKKβ mRNA nanoparticles
02
Targets
IRF5 (Interferon regulatory factor 5)RELA (Nuclear Factor Kappa B Subunit p65)IKBKB (IKKβ)
Beyond the preview
Go deeper on interferon regulatory factor 5 messenger RNA nanoparticles + I-kappa-B kinase beta messenger RNA nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon regulatory factor 5 messenger RNA nanoparticles + I-kappa-B kinase beta messenger RNA nanoparticles.